Skip to main content
. Author manuscript; available in PMC: 2017 Aug 1.
Published in final edited form as: JAMA Oncol. 2016 Aug 1;2(8):1014–1022. doi: 10.1001/jamaoncol.2016.0173

Figure 1.

Figure 1

(A) The sensitivity of plasma ddPCR for the detection of EGFR and KRAS mutations increases directly with the number of metastatic sites present in a given patient (p<0.001). (B) Dynamic range of plasma genotyping using a validated ddPCR-based assay. Wide dynamic range and the absence of false positives are noted for the detection of KRAS G12X and EGFR sensitizing mutations. A small number of false positives are seen with the EGFR T790M assay – potentially secondary to tumor heterogeneity with respect to acquired resistance mechanisms (n=174).